Welcome to our dedicated page for SeaStar Medical Holding news (Ticker: ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding stock.
SeaStar Medical Holding Corporation (Nasdaq: ICU) generates news that centers on its development and commercialization of therapies based on its patented Selective Cytopheretic Device (SCD) technology for critically ill patients. Company press releases highlight progress with its first commercial product, QUELIMMUNE (SCD-PED) therapy, which is approved by the U.S. Food and Drug Administration under a Humanitarian Device Exemption for life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients receiving Renal Replacement Therapy.
News updates frequently cover commercial adoption milestones for QUELIMMUNE, including new top-rated children’s hospitals that begin using the therapy and real-world outcomes reported through the SAVE Surveillance Registry. These releases often describe survival data, safety findings such as zero device-related adverse events, and registry enrollment updates that may influence the therapy’s market opportunity.
Investors following ICU news also see regular coverage of clinical development for SCD therapy in adult AKI and cardiovascular indications. This includes announcements related to the NEUTRALIZE-AKI pivotal trial in adults with AKI requiring continuous renal replacement therapy, DSMB recommendations, enrollment progress, and the initiation of studies such as the NEUTRALIZE-CRS trial in patients with acute chronic systolic heart failure and cardiorenal syndrome awaiting LVAD implantation.
Additional SeaStar Medical news items include regulatory and FDA interactions, such as Breakthrough Device Designations for multiple therapeutic indications and adjustments to post-approval surveillance requirements for QUELIMMUNE. Corporate updates, including reverse stock split actions, equity financings, financial results, and executive appointments, are also disclosed through press releases and associated SEC filings. For readers tracking ICU, the news stream provides insight into commercial traction, clinical trial status, regulatory milestones, and key corporate decisions that shape the company’s SCD-based therapy platform.
SeaStar Medical Holding Corporation (Nasdaq: ICU) announced a $3.3 million tranche closing of a $9.8 million private placement with a single institutional investor. The investment is structured as a Senior Unsecured Original Issue 8.0% Discount Convertible Note, yielding approximately $3.0 million in proceeds. The Note matures in 15 months and can be converted into stock at an initial price of $2.70. The investor also receives warrants for 328,352 shares at an exercise price of $2.97. Following regulatory conditions, SeaStar may secure additional tranches totaling $8.8 million, aiming to enhance its financial stability and product development efforts.
SeaStar Medical Holding Corporation (Nasdaq: ICU) announced its upcoming presentation at the Emerging Growth Virtual Conference on March 22, 2023, at 2:15 p.m. Eastern time. The event will feature CEO Eric Schlorff and CMO Kevin Chung, outlining the company's innovative solutions aimed at reducing hyperinflammation effects on vital organs. Attendees can register for the presentation and submit questions in advance. Following the event, a replay will be available on the company’s and conference's respective websites. SeaStar Medical focuses on developing proprietary extracorporeal therapies for critically ill patients.
SeaStar Medical (Nasdaq: ICU) announces that Dr. Kevin Chung will present the company's Selective Cytopheretic Device (SCD) at the 5th Chronic Kidney Disease Drug Development Summit on March 7, 2023. The presentation will focus on the SCD's role in addressing systemic inflammation, a key factor in organ dysfunction, particularly in Acute Kidney Injury (AKI) and COVID-19 cases. The SCD offers a novel approach by targeting activated pro-inflammatory cells, helping restore homeostasis in critically ill patients. SeaStar Medical has received FDA approval for a pivotal study evaluating the SCD's safety and efficacy in adults with AKI requiring continuous kidney replacement therapy.
SeaStar Medical (Nasdaq: ICU) has announced the launch of its pivotal NEUTRALIZE-AKI study, aimed at assessing the safety and efficacy of its Selective Cytopheretic Device (SCD) for adults with acute kidney injury (AKI) needing continuous kidney replacement therapy (CKRT). Starting in March, the randomized controlled trial will enroll up to 200 patients across 30 U.S. sites. The study's primary endpoint focuses on 90-day mortality and dialysis dependency, while secondary endpoints include Day 28 mortality and ICU-free days. Previous studies indicate the SCD may significantly reduce mortality rates, showcasing its potential as a life-saving solution for critically ill patients.
SeaStar Medical (Nasdaq: ICU) announced a conference call on February 15, 2023, at 4:00 p.m. ET to discuss significant business updates. Key topics will include FDA approval for a pivotal trial of its Selective Cytopheretic Device (SCD) aimed at treating adults suffering from acute kidney injury (AKI) due to hyperinflammation. Additionally, updates on the Humanitarian Device Exemption (HDE) submission for use in critically ill children will be shared. The conference call will be accessible via phone or through a live webcast, and a replay will be available for 48 hours post-call.
SeaStar Medical (Nasdaq: ICU) has received FDA approval for its investigational device exemption (IDE) to conduct a pivotal study of its Selective Cytopheretic Device (SCD). This 200-patient trial will evaluate the SCD's effectiveness in treating acute kidney injury (AKI) patients requiring continuous kidney replacement therapy (CKRT). Enrollment is set to begin in March 2023, with interim results anticipated in Q4 2023 and topline results by mid-2024. The SCD targets pro-inflammatory immune cells to mitigate hyperinflammation, a condition linked to high mortality rates in AKI patients. SeaStar aims to redefine treatment protocols in critical care environments.
SeaStar Medical (Nasdaq: ICU) announced that CEO Eric Schlorff will present a company overview at the virtual Sequire Biotechnology Conference on February 2, 2023, at 3:30 p.m. Eastern Time. The conference will focus on SeaStar's innovative solutions aimed at mitigating hyperinflammation's effects on vital organs. Attendees can register for the event through the Sequire Biotechnology website. An archived webcast of the presentation will also be available on the SeaStar Medical website.
SeaStar Medical has submitted an investigational device exemption (IDE) application to the FDA for a pivotal study of its Selective Cytopheretic Device (SCD) aimed at treating adults with acute kidney injury (AKI) needing continuous kidney replacement therapy (CKRT). The study will enroll 200 participants, focusing on 90-day mortality and dialysis dependency rates. Interim results are expected by Q4 2023, with topline results and Pre-market Approval anticipated by Q3 2024. The SCD has previously shown promise in reducing mortality rates in critically ill patients.
SeaStar Medical Holding Corporation (Nasdaq: ICU) has signed an exclusive U.S. license and distribution agreement with Nuwellis, Inc. for its Selective Cytopheretic Device (SCD) to treat acute kidney injury (AKI) in children. Nuwellis will promote SCD to pediatric nephrologists and intensive care doctors. An FDA review for SCD's Humanitarian Device Exemption is anticipated in Q1 2023, with a potential U.S. launch in Q2 2023. The therapy aims to mitigate inflammation in critically ill pediatric patients, potentially reducing ICU stays and dialysis dependency.
SeaStar Medical (Nasdaq:ICU) has appointed Thomas R. Mullen as Vice President of Operations and Product Development. With over 30 years in the medical device field, Mullen aims to drive the growth and commercialization of SeaStar's innovative therapies targeting hyperinflammation in vital organs. He previously served as a consultant to the company since 2020 and brings extensive experience in operations and regulatory compliance. The company’s Selective Cytopheretic Device is currently under FDA evaluation for a Humanitarian Device Exemption for treating acute kidney injury, with potential commercialization expected in mid-2023.